Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy
These data suggest that the 52-gene signature can be used in patients with IPF treated with antifibrotic therapy to distinguish patients at higher risk of disease progression and mortality.
Authors
- Julia F. Söllner
- Stefan Bentink
- Thomas Schlange (ORCID: https://orcid.org/0000-0002-2027-3976)
- Megan L. Neely (ORCID: https://orcid.org/0000-0002-0101-1081)
- Richard Vinisko (ORCID: https://orcid.org/0000-0001-9045-3027)
- Jamie L. Todd (ORCID: https://orcid.org/0000-0003-4247-3693)
- Christian Heßlinger
- Margaret L. Salisbury (ORCID: https://orcid.org/0000-0001-8217-6955)
- Thomas B. Leonard (ORCID: https://orcid.org/0000-0003-3098-4330)
- Nina Patel
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Clinical Research Institute (US)
- Duke Medical Center (US)
- Boehringer Ingelheim (United States) (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Lung
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1007/s00408-024-00742-x
- Citations
- 4
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Boehringer Ingelheim
- AstraZeneca
- Sanofi
- CareDx
- Natera
- National Institutes of Health
- Duke Clinical Research Institute